Lund District Court declared Diagonal Bio AB bankrupt on December 11, 2025; NGM halted trading the same day and, citing Nordic SME rule 3.3.2, has delisted the company’s shares with immediate effect (last trading day 2025-12-11), trading will not be resumed — listing: DIABIO, ISIN SE0015961826. The notice formally removes the instrument from the NSME segment and informs investors that the security is no longer tradable on Nordic SME.
Lund District Court declared Diagonal Bio AB bankrupt on December 11, 2025, and Nordic Growth Market (NGM) placed a trading halt the same day before invoking Nordic SME Rule 3.3.2 to delist the company's shares with immediate effect; the last day of trading is recorded as 2025-12-11 and the security will not be resumed (Listing: DIABIO, ISIN SE0015961826). The notice is administrative and confirms the company has either filed for or been subject to bankruptcy proceedings, triggering automatic delisting authority under the exchange rule cited. Immediate practical impact is that shareholders cannot liquidate positions on Nordic SME and existing equity claims will now be resolved through Swedish bankruptcy procedures; equity holders rank behind secured and unsecured creditors, implying low to nil recovery prospects absent unexpected asset value. NGM’s market notice and the formal delisting remove the instrument from the NSME segment and transfer all recovery information to bankruptcy filings and court administration. Broader market impact is limited (market impact score ~0.25) and the development is primarily a legal/credit event within the small-cap biotech segment rather than a systemic concern. Investors should monitor official bankruptcy filings, creditor notices and any asset-sale announcements to assess residual recovery value and timing.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly negative
Sentiment Score
-0.80
